Morgan Stanley still expects Sarepta to get approval for SRP-9001
The Fly

Morgan Stanley still expects Sarepta to get approval for SRP-9001

Morgan Stanley notes STAT News’ report yesterday that a group of reviewers at the FDA did not want to approve SRP-9001 and that Peter Marks stepped in and scheduled an advisory committee meeting, or AdCom. Following STAT’s report, the analyst does not find tension among FDA staff surprising and "would expect it throughout the review process." However, the firm expects a supportive AdCom based on the evidence supporting the surrogate endpoint and while it continues to expect volatility through then, Morgan Stanley expects "ultimate approval" for SRP-9001. The firm has an Overweight rating and $183 price target on Sarepta shares.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on SRPT:

Related Articles
TheFlySarepta management to meet with Cantor Fitzgerald
TipRanks Auto-Generated NewsdeskSarepta Therapeutics Expands Board, Welcomes New Director
TheFlyElection 2024: Where To Put Your Money Ahead of the Vote
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App